TLR3 and sarcoma: Furthermore, an exogenous supply of type I IFNs was shown to restore chemotherapeutic responses to DOX in Toll-like receptor 3 (Tlr3)−/− sarcomas growing in mice,10 supporting the use of IFN-β in augmenting DOX efficacy.9